PODD
Insulet Corporation
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Aggressive Growth profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 50.0 reflects a balance between a strong momentum reading (15.4) and a moderate profitability score (14.4) on one side, offset by a growth sub-score of only 11.0 and a financial health sub-score of 12.0 that cap the total.
- The zero scores in dividend (0.0) and theme (0.0) account for a meaningful absence of scoring contribution — together those two categories represent up to 40 points of potential model capacity, and Insulet captures none of it, anchoring the ceiling.
- Eight out of ten core metrics were mappable from the EDGAR 10-K filing, providing high data confidence at 8.0/10, which means the 50.0 score is a well-supported reading rather than an estimate filled with defaults.
Why Not Higher
- The growth sub-score of 11.0 out of 20 indicates that year-over-year improvements in revenue, net income, and EPS have been inconsistent or insufficient in magnitude to earn a higher rating, which prevents the model from treating Insulet as a top-tier growth compounder despite its market position.
- The combined zero contribution from the dividend and theme sub-scores means Insulet cannot access up to 40 points of model capacity, and without macro theme recognition or any free cash flow-based capital return program, the composite score is structurally limited regardless of how well the operating metrics perform.
Data Confidence
8 / 10
High — most data fields present
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Insulet Corporation is a U.S.-based medical device company best known for its OmniPod insulin management system, a tubeless, wearable patch pump designed for people with diabetes. Unlike traditional insulin delivery methods, OmniPod eliminates the need for tubing and provides continuous subcutaneous insulin delivery, positioning Insulet in the rapidly growing diabetes technology market alongside continuous glucose monitoring integration. The company's FY2025 10-K filing underpins a composite model score of 50.0/100, reflecting a research candidate that demonstrates operational momentum and improving fundamentals but has not yet translated those into the kind of sustained profitability metrics that would push the score materially higher. The momentum sub-score of 15.4 is the strongest contributor, signaling quarter-over-quarter improvement in revenue, earnings, and margins as captured in EDGAR filings, while profitability at 14.4 reflects positive but still developing margin structure. Growth at 11.0 and financial health at 12.0 contribute meaningfully but also point to areas where leverage and bottom-line consistency remain research considerations. The key tradeoff for this research candidate is between a compelling operational trajectory in a high-growth device category and the financial health constraints — particularly leverage — that introduce risk even as the business scales.
Plain English
Insulet makes the OmniPod, a tubeless insulin pump worn directly on the body by people with diabetes — it's one of the leading wearable drug delivery devices in the world. A model score of 50.0 out of 100 means the company shows real promise, especially in recent quarterly improvement, but hasn't yet earned top marks because profitability and balance sheet strength are still works in progress. The Medium risk rating reflects that this is a growth-stage medical device business with real revenue and improving margins, but it carries debt and isn't yet delivering the consistent bottom-line results of a fully mature company. For a researcher with an aggressive growth goal profile, this would be worth examining more closely rather than passing over.
Bull Case vs. Bear Case
Bull Case
- The momentum sub-score of 15.4 out of 20 — the highest individual sub-score in the model — indicates consistent sequential improvement in revenue, earnings, and margins across quarterly filings, suggesting the business is executing well on its growth plan.
- The profitability sub-score of 14.4 out of 20 reflects improving net and operating margins, indicating that Insulet is beginning to convert its top-line OmniPod revenue growth into more meaningful bottom-line results as the device scales globally.
- Insulet's aggressive growth goal profile alignment, with a best-scoring profile of 58.0 in that category, suggests the underlying filing data supports a narrative of a company in active revenue expansion, which is consistent with OmniPod's penetration into international markets and the Type 1 and Type 2 diabetes addressable population.
Bear Case
- The financial health sub-score of 12.0 out of 20 points to leverage concerns captured in the balance sheet filings, suggesting the company carries a debt load that could limit financial flexibility if revenue growth were to decelerate or margins compress.
- The growth sub-score of 11.0 out of 20 is moderate rather than exceptional, indicating that year-over-year revenue, net income, and EPS growth as reported in the 10-K have not been uniformly strong enough to push this metric into the top tier of the model.
- The dividend sub-score of 0.0 and theme sub-score of 0.0 together contribute nothing to the total score of 50.0, meaning this research candidate is entirely dependent on operational and financial execution with no structural scoring support from income generation or macro tailwinds recognized by the model.
What Could Change the Picture
Bullish Triggers
- A sustained improvement in the growth sub-score — driven by accelerating year-over-year EPS and net income growth visible in future 10-K filings — would signal that Insulet's revenue scale is translating into durable bottom-line expansion, which could push the composite score materially above 50.
- Reduction in the leverage ratio and improvement in interest coverage as reported in future balance sheet filings would strengthen the financial health sub-score above 12.0, indicating the company is deleveraging while growing and reducing the structural risk embedded in the current model reading.
Bearish Triggers
- A deterioration in the momentum sub-score — reflecting sequential quarterly declines in revenue or margin compression in future EDGAR filings — would remove the strongest contributor to the current 50.0 score and raise serious questions about whether OmniPod's growth trajectory is decelerating.
- Any increase in leverage or decline in interest coverage captured in future 10-K filings, particularly if accompanied by weaker-than-expected net margin performance, would push the financial health sub-score below 12.0 and reinforce the bear case that the balance sheet is a constraint on long-term value creation.
Red Flags
- The financial health sub-score of 12.0 out of 20, combined with a growth sub-score of only 11.0, raises the question of whether leverage on the balance sheet is being serviced comfortably — the interest coverage metric embedded in that sub-score warrants close scrutiny from the 10-K disclosures.
- The overall model score of 50.0 sits exactly at the midpoint of the 0-100 range, and the weakest scoring profile is dividend income at 42.4, reinforcing that this is a company with no capital return mechanism and a financial profile that requires continued revenue execution to justify its balance sheet structure.
Risk Profile
Medium RiskThe Medium risk rating for Insulet reflects a company with real and improving commercial operations in a validated medical device category, but with a leveraged balance sheet and not-yet-mature profitability profile that introduce meaningful downside sensitivity if revenue growth or margin expansion falter. It is not the binary risk of an early-stage startup, but nor does it carry the financial fortress characteristics of a large-cap medical device incumbent.
Key Catalysts to Watch
The key catalysts to monitor from future SEC filings are sequential improvement in operating and net margins — which would lift both the profitability and momentum sub-scores — and any material change in the debt-to-equity or interest coverage metrics that would either validate or challenge the current financial health reading of 12.0 out of 20.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.